MOTS-c is routinely marketed as "exercise in a vial." That phrase does not appear in the research. "Exercise mimetic" does, but it is a narrow technical term that means something much more specific, and much less exciting, than the marketing implies. Here is what a mitochondrial-derived peptide actually is, what the AMPK research proposes, what the human exercise data does and does not show, and where the wires get crossed.
The Genuinely Strange Thing About MOTS-c
Start with the part that is real, because it is more interesting than the sales copy.
Almost every peptide discussed in this space is encoded in nuclear DNA, the genome sitting in the cell's nucleus. MOTS-c is not. It is encoded inside mitochondrial DNA, the small circular genome that mitochondria carry independently, a legacy of the ancient endosymbiotic event that brought them into our cells in the first place.
In 2015, researchers at the University of Southern California's Leonard Davis School of Gerontology reported a short open reading frame within the mitochondrial 12S rRNA gene that encodes a 16 amino acid peptide. They named it MOTS-c, for mitochondrial open reading frame of the 12S rRNA-c. The paper was published in Cell Metabolism (PMID 25738459).
MOTS-c was not the first of its kind. An earlier mitochondrial-encoded signaling peptide, humanin, had already suggested that more were likely hiding in the mitochondrial genome. Together they form a class now called mitochondrial-derived peptides, or MDPs.
The conceptual shift matters: mitochondria are not only cellular power plants but also signaling units that can send messages outward, including messages that reach nuclear gene expression. That is a legitimately notable idea in cell biology. It is also, notably, not a claim about anyone's body composition.
What "Exercise Mimetic" Means in the Literature
The term predates MOTS-c by years. It entered wide circulation with a 2008 paper in Cell by Narkar and colleagues titled "AMPK and PPARdelta agonists are exercise mimetics" (PMID 18674809). It described compounds that switch on some of the same intracellular signaling that endurance training switches on in muscle, studied in mice.
Read what that term actually claims: overlap at the level of a signaling pathway. It does not claim equivalence of outcome. Inside the literature, "exercise mimetic" is mechanistic shorthand, much closer to "engages an exercise-responsive pathway" than to "does what exercise does." It describes where a molecule acts, not what it achieves.
The distortion happens in a single step, when the phrase leaves the journal and gets read as a promise rather than as a pathway label. Almost everything misleading about MOTS-c marketing traces back to that one translation error.
The AMPK Link, and What It Establishes
AMPK is a cellular energy sensor. It becomes more active when a cell's energy charge drops, and it is one of the most heavily studied nodes in exercise biology because working muscle activates it.
The mechanism proposed in the 2015 paper is indirect and fairly specific: MOTS-c was reported to interfere with the folate cycle and the de novo purine biosynthesis tethered to it, with AMPK activation following downstream. Skeletal muscle appeared to be the primary target tissue. The experimental work described in that paper was conducted in cells and in mice, and it addressed metabolic regulation in those models.
Here is the part usually left out. AMPK is a hub, not a destination. Fasting activates AMPK. So do hypoxia and a range of ordinary cellular stresses. Sharing an upstream switch with exercise does not make a molecule a form of exercise, any more than sharing a highway on-ramp makes two cars the same vehicle.
And findings in cells and mice are hypotheses about humans, not conclusions about them. That is not a technicality. It is the single most common failure point when preclinical research gets repackaged for consumers.
What the Human Data Actually Shows
Two human-relevant findings are worth knowing, and both are narrower than the marketing suggests.
The first comes from a 2021 Nature Communications paper by Reynolds and colleagues, also from USC (PMID 33473109). Most of that study is mouse work. Its human component is an observation: exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation.
The second is more instructive precisely because it is less tidy. A 2021 study in the Journal of Applied Physiology from Karolinska Institutet (PMID 34351816) randomized 30 subjects to acute endurance exercise (45 minutes of cycling at roughly 70 percent of estimated VO2max), acute resistance exercise, or a control condition, and measured plasma humanin and MOTS-c before exercise and at 30 minutes and 3 hours after.
The results were mixed. Humanin rose significantly after endurance exercise but not after resistance exercise. MOTS-c showed a trend toward an increase after endurance exercise. A trend is not a statistically significant result, and it is worth saying so plainly rather than rounding it up. The authors also reported that plasma MDP levels were not correlated with fitness measures including VO2max, leg strength, and muscle mitochondrial DNA copy number.
Now the load-bearing detail. Both studies measured MOTS-c that the body produced on its own. Neither administered MOTS-c to human participants. The published human literature is largely observational measurement of a naturally occurring peptide, not testing of a peptide given as a treatment.
Why "Associated With Exercise" Is Not "Replaces Exercise"
The marketing claim compresses three separate logical steps into one. Pulled apart, they look very different:
- Exercise is associated with a rise in circulating MOTS-c. Partially supported, and stronger in some studies than others.
- Therefore MOTS-c mediates what exercise does. Not established. Exercise changes hundreds of circulating factors simultaneously, and a molecule that moves alongside a stimulus may be a bystander rather than a mediator.
- Therefore administering MOTS-c reproduces the effects of exercise. Not tested in humans.
Step one is a measurement. Step three is a product pitch. The distance between them is most of a research program.
A simpler way to hold it: body temperature rises when you run. Warming someone up is not a workout.
There is also a scale problem. Exercise is a whole-organism stimulus: mechanical loading of bone and connective tissue, cardiovascular and respiratory demand, neural adaptation, and downstream effects on sleep, appetite and mood. Nothing in the MOTS-c literature proposes a shortcut around a stimulus that broad, and the researchers who described the peptide did not claim one. "Exercise in a vial" is a marketing artifact, not a scientific position.
Where MOTS-c Stands With the FDA
MOTS-c is a research peptide. It is not FDA-approved for any indication.
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding MOTS-c to the 503A Bulks List, against FDA staff's own pre-meeting recommendation not to add it. PCAC recommendations are advisory and non-binding. Before anything takes effect, the FDA must complete notice-and-comment rulemaking, a process that can take 12 months or more. Nothing has changed yet in what may lawfully be compounded.
For the full breakdown of that vote and what still has to happen, see the TelosRX explainer on the July 2026 FDA PCAC vote. For background on the peptide itself, see the TelosRX MOTS-c research overview. For general context on how research peptides differ from approved medications, see our discussion of peptide safety questions.
Frequently Asked Questions
Is MOTS-c "exercise in a vial"?
No. That phrase comes from marketing, not from the research literature. Studies have observed that endogenous MOTS-c levels can change around exercise, but observing that a molecule moves alongside exercise is not the same as showing it reproduces exercise. No published human trial has tested administered MOTS-c against exercise.
What does "exercise mimetic" actually mean in research?
It is mechanistic shorthand for a compound that engages some of the same intracellular signaling pathways that exercise engages, particularly in muscle. The term was popularized by a 2008 Cell paper on AMPK and PPARdelta agonists. It describes pathway overlap, not equivalent outcomes, and it is not a claim that a molecule substitutes for training.
Is MOTS-c really encoded in mitochondrial DNA?
Yes, and this is the most interesting verified fact about it. MOTS-c is a 16 amino acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene, rather than in nuclear DNA. It belongs to a class called mitochondrial-derived peptides, alongside humanin.
Does MOTS-c go up when people exercise?
The evidence is mixed rather than uniform. A 2021 Nature Communications paper reported that exercise induces endogenous MOTS-c expression in human skeletal muscle and in circulation. A separate 2021 controlled study in the Journal of Applied Physiology found that MOTS-c showed only a trend toward an increase after acute endurance exercise, which did not reach statistical significance, while humanin rose significantly.
Has MOTS-c been given to people in clinical trials?
The published human literature on MOTS-c consists largely of studies measuring the peptide the body produces naturally, in contexts such as exercise or disease. It does not consist of trials administering MOTS-c to participants. Anyone citing human outcome data for administered MOTS-c should be asked for the specific study.
Is MOTS-c FDA-approved?
No. MOTS-c is not FDA-approved for any indication. An FDA advisory committee voted in July 2026 to recommend adding it to the 503A Bulks List, but that recommendation is advisory and non-binding, rulemaking has not been completed, and nothing about its legal compounding status has changed.
This article is educational and is not medical advice. MOTS-c is a research peptide and is not FDA-approved for any indication. Nothing here describes MOTS-c as a treatment for any condition, and no claim is made that MOTS-c affects body weight, body composition, metabolic health, physical performance or lifespan in humans. Findings from cell and animal models do not establish effects in people. The July 2026 PCAC vote is an advisory, non-binding recommendation; FDA rulemaking is not complete and no change in legal compounding status has taken effect. Compounded medications are not FDA-approved and are prepared under federal and state compounding regulations. Any prescription requires review by a US-licensed provider, and approval is not guaranteed. TelosRX is LegitScript-certified and operates as an online-first, asynchronous telehealth service.